Ocugen, Inc. to Present Preclinical Results at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting
29 avr. 2022 11h36 HE
|
Ocugen
MALVERN, Pa., April 29, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing and commercializing novel gene therapies, biologicals and...
ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa
11 déc. 2019 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Dec. 11, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA...
ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
21 nov. 2019 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, Netherlands and CAMBRIDGE, Mass., Nov. 21, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of...
ProQR Announces Positive Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients
10 oct. 2019 06h00 HE
|
ProQR Therapeutics N.V.
Reported rapid, significant and durable improvements in vision at twelve monthsConcordant improvement in key secondary outcome measuresThe target registration dose of sepofarsen was well-tolerated...
Blueprint Genetics, InformedDNA and the Foundation Fighting Blindness launch an open access program for patients with inherited retinal disease in the United States
02 oct. 2019 07h00 HE
|
Foundation Fighting Blindness
COLUMBIA, Maryland, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Blueprint Genetics, InformedDNA and the Foundation Fighting Blindness have announced that beginning in October 2019, a new open-access program...
ProQR to Present at the JMP Securities Life Sciences Conference
03 juin 2019 07h00 HE
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands and CAMBRIDGE, Mass., June 03, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative...
ProQR Announces “ProQR Vision 2023” Strategy at its Annual R&D Day
29 janv. 2019 08h30 HE
|
ProQR Therapeutics N.V.
LEIDEN, the Netherlands & CAMBRIDGE, Mass., Jan. 29, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative...